Insilico, Teva team to apply predictive Digital Twins for biopharmaceutical production
STUTTGART, Germany — Insilico Biotechnology AG and Teva Pharmaceutical Industries Ltd. announced an agreement to apply Insilico’s technology for predictive biomanufacturing to create and implement more efficient production processes of Teva’s biopharmaceutical therapeutics. The ever increasing demand of high-quality biopharmaceutical therapies such as monoclonal antibodies requires more than ever highly efficient and robust production technologies.
